Von Willebrand disease - the 'Dos' and 'Don'ts' in surgery

Research output: Contribution to journalArticle


Von Willebrand disease (VWD) is the most common genetic bleeding disorder. VWD is caused by a deficiency or dysfunction of von Willebrand factor (VWF), a plasma protein that mediates the initial adhesion of platelets at sites of vascular injury and binds and stabilises coagulation factor VIII (FVIII) in the blood. Prophylaxis of surgical bleeding in patients with VWD requires consideration of the individual situation, including the type of procedure and the bleeding rate, before decisions about treatment type, dose, duration and adjunctive therapy with antifibrinolytics or antithrombotic prophylaxis can be made. Although desmopressin (DDAVP)-stimulated release of endogenous VWD is an effective treatment strategy in many patients, plasma concentrates containing VWF are the preferred option for most patients undergoing surgical procedures. Recommendations for the management of surgery in patients with VWD are summarised, including the severity of VWD and the type of the surgical procedure.


External organisations
  • Skåne University Hospital
  • Goethe University
Research areas and keywords

Subject classification (UKÄ) – MANDATORY

  • Hematology


  • Desmopressin, Recommendation, Surgery, Thromboembolic event, Von Willebrand disease, Von Willebrand factor concentrate
Original languageEnglish
Pages (from-to)121-127
JournalEuropean Journal of Haematology
Issue number2
Early online date2016
Publication statusPublished - 2017
Publication categoryResearch